Stereochemistry | ACHIRAL |
Molecular Formula | C27H20F3N9 |
Molecular Weight | 527.5032 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1C2=C(N(\C1=N\C#N)C3=CN=C(C=C3)C(C)(C)C#N)C4=CC(=CC=C4N=C2)C5=CN=C(N)C(=C5)C(F)(F)F
InChI
InChIKey=VJLRLTSXTLICIR-AUGOTPMTSA-N
InChI=1S/C27H20F3N9/c1-26(2,13-31)22-7-5-17(11-35-22)39-23-18-8-15(16-9-19(27(28,29)30)24(33)36-10-16)4-6-20(18)34-12-21(23)38(3)25(39)37-14-32/h4-12H,1-3H3,(H2,33,36)/b37-25+
Molecular Formula | C27H20F3N9 |
Molecular Weight | 527.5032 |
Charge | 0 |
Count |
MOL RATIO
1 MOL RATIO (average) |
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Optical Activity | NONE |
Panulisib (P7170) was developed as a small molecule inhibitor of phosphatidylinositol 3-kinase (PI3K) and mTOR with potential anticancer activity. It is known that mTOR pathway is often upregulated in cancer and thus intensively pursued as a target to design novel anticancer therapies. P7170 were being tested in phase I clinical studies in patients with advanced refractory solid tumors. The primary objective was to determine the maximum tolerated dose and dose-limiting toxicity of the drug. However, this study is suspended because of the sponsor’s decision.